Here is the design of a clinical trial:

Official Title: A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial

Included conditions:
- Stage III Esophageal Squamous Cell Carcinoma

Study Armgroups:
- {'label': 'Paclitaxel and Cisplatin (TP)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients receive TP concurrent with radiotherapy (1.8Gy/d, d1-5/week, 34Fx) Paclitaxel: 175mg/m2/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m2/d, ivgtt, d1-3, q4w\\*4', 'interventionNames': ['Drug: Paclitaxel and Cisplatin', 'Radiation: Radiotherapy']}
- {'label': 'Paclitaxel and Fluorouracil (TF)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients receive TF concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; 5-FU 300mg/m2, civ 96h, d1-4, qw\\*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m2, civ 72h, d1-3, q4w\\*2', 'interventionNames': ['Drug: Paclitaxel and Fluorouracil', 'Radiation: Radiotherapy']}
- {'label': 'Paclitaxel and Carboplatin（TC）', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients receive TC concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1, qw\\*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1, q4w\\*2', 'interventionNames': ['Drug: Paclitaxel and Carboplatin', 'Radiation: Radiotherapy']}

Interventions:
- {'type': 'DRUG', 'name': 'Paclitaxel and Cisplatin', 'description': 'patients get Paclitaxel and Cisplatin according to protocol', 'armGroupLabels': ['Paclitaxel and Cisplatin (TP)'], 'otherNames': ['TP']}
- {'type': 'DRUG', 'name': 'Paclitaxel and Fluorouracil', 'description': 'patients get Paclitaxel and Fluorouracil according to protocol', 'armGroupLabels': ['Paclitaxel and Fluorouracil (TF)'], 'otherNames': ['TF']}
- {'type': 'DRUG', 'name': 'Paclitaxel and Carboplatin', 'description': 'patients get Paclitaxel and Carboplatin according to protocol', 'armGroupLabels': ['Paclitaxel and Carboplatin（TC）'], 'otherNames': ['TC']}
- {'type': 'RADIATION', 'name': 'Radiotherapy', 'description': '1.8Gy/d, d1-5/week, 34Fx', 'armGroupLabels': ['Paclitaxel and Carboplatin（TC）', 'Paclitaxel and Cisplatin (TP)', 'Paclitaxel and Fluorouracil (TF)']}

Primary Outcomes:
- {'measure': 'overall survival', 'timeFrame': '3 years'}

Please estimate the sample size based on the assumption: 
Power of 80%, two-sided significance level (α) of 0.025, accrual period of 48 months, minimum follow-up period of 24 months, and dropout rate of 10%.
Sample size calculation and statistical analysis
        This three-arm randomised trial is designed to confirm whether TF is superior to TP or TC concurrent with radiotherapy in terms of overall survival. According to RTOG 0113 and other reports, median survival time of TF concurrent with radiotherapy for oesophageal cancer is 28.7 months, while TP 14.9 months5and TC 17.4âmonths13. According to the Schoenfeld and Richterâs method, the sample size of 107 patients per arm (154 events in total) is required to warrant a power of 80% at a two-sided Î± level of 0.025 for the comparison between TP and TF with relatively smaller difference, assuming an accrual period of 48 months, a minimum follow-up period of 24 months and a dropout rate of 10%.14 15 The total sample size is planned as 321 patients (107 patients in each arm, a total of 231 events).
        The median overall survival will be estimated with Kaplan-Meier method, and log-rank test will be used to compare the overall survival among treatment arms. We will conduct a subgroup analyses to test whether the treatment effects differ among subgroups (N0, N1, M1a).